healthcare system between $13.5 and $27.2 billion each year. Published research in Thrombosis & Haemostasis shows VTEs cost the U.S.
VTE is a collective term encompassing deep vein thrombosis (DVT), a blood clot in a deep vein usually the leg, and pulmonary embolism (PE), when a clot travels to the lung. VTE affects more than 900,000 Americans each year one-third of these episodes will be fatal. The economic analysis, presented today at the Hospital Medicine 2016 congress, compared the cost savings associated with treatment with XARELTO®, a non-vitamin K antagonist oral anticoagulant (NOAC), to warfarin in the hospital setting. hospitals using XARELTO® (rivaroxaban) instead of warfarin to treat patients diagnosed with a venous thromboembolism (VTE) may save, on average, almost $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days. SAN DIEGO, CA (March 7, 2016) – A new, real-world study found U.S.
